Nang Kuang Pharmaceutical Co Ltd
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally. The company offers ready to use injections, such as prefilled syringe injections and premixed IV infusions; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion.… Read more
Nang Kuang Pharmaceutical Co Ltd (1752) - Net Assets
Latest net assets as of December 2025: NT$2.49 Billion TWD
Based on the latest financial reports, Nang Kuang Pharmaceutical Co Ltd (1752) has net assets worth NT$2.49 Billion TWD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.82 Billion) and total liabilities (NT$1.33 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$2.49 Billion |
| % of Total Assets | 65.12% |
| Annual Growth Rate | 7.22% |
| 5-Year Change | 11.14% |
| 10-Year Change | 17.26% |
| Growth Volatility | 15.24 |
Nang Kuang Pharmaceutical Co Ltd - Net Assets Trend (2009–2025)
This chart illustrates how Nang Kuang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nang Kuang Pharmaceutical Co Ltd (2009–2025)
The table below shows the annual net assets of Nang Kuang Pharmaceutical Co Ltd from 2009 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$2.49 Billion | +2.80% |
| 2024-12-31 | NT$2.42 Billion | +1.89% |
| 2023-12-31 | NT$2.38 Billion | -1.41% |
| 2022-12-31 | NT$2.41 Billion | +7.63% |
| 2021-12-31 | NT$2.24 Billion | +1.62% |
| 2020-12-31 | NT$2.20 Billion | +0.79% |
| 2019-12-31 | NT$2.19 Billion | +6.53% |
| 2018-12-31 | NT$2.05 Billion | -4.20% |
| 2017-12-31 | NT$2.14 Billion | +0.95% |
| 2016-12-31 | NT$2.12 Billion | +6.46% |
| 2015-12-31 | NT$1.99 Billion | +38.36% |
| 2014-12-31 | NT$1.44 Billion | +1.11% |
| 2013-12-31 | NT$1.43 Billion | +53.62% |
| 2012-12-31 | NT$928.02 Million | +15.66% |
| 2011-12-31 | NT$802.34 Million | -0.13% |
| 2010-12-31 | NT$803.36 Million | -1.56% |
| 2009-12-31 | NT$816.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nang Kuang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1075.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$907.19 Million | 36.52% |
| Other Components | NT$1.58 Billion | 63.48% |
| Total Equity | NT$2.48 Billion | 100.00% |
Nang Kuang Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Nang Kuang Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Datalex
IR:DLE
|
$46.93 Million |
|
Lotte Chemical Titan Holding BHD
KLSE:5284
|
$46.93 Million |
|
Duksung Co Ltd
KO:004835
|
$46.93 Million |
|
Hi-Lai Foods Co Ltd
TWO:1268
|
$46.94 Million |
|
Noble Development Public Company Limited
BK:NOBLE
|
$46.91 Million |
|
Eisen- und Hüttenwerke AG
F:EIS
|
$46.90 Million |
|
GD Express Carrier Bhd
KLSE:0078
|
$46.90 Million |
|
Bank Nationalnobu Tbk
JK:NOBU
|
$46.88 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nang Kuang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,421,961,000 to 2,484,138,000, a change of 62,177,000 (2.6%).
- Net income of 243,948,000 contributed positively to equity growth.
- Dividend payments of 80,791,000 reduced retained earnings.
- Other comprehensive income decreased equity by 297,369,999.
- Other factors increased equity by 196,389,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$243.95 Million | +9.82% |
| Dividends Paid | NT$80.79 Million | -3.25% |
| Other Comprehensive Income | NT$-297.37 Million | -11.97% |
| Other Changes | NT$196.39 Million | +7.91% |
| Total Change | NT$- | 2.57% |
Book Value vs Market Value Analysis
This analysis compares Nang Kuang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.48x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.62x to 1.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | NT$13.94 | NT$36.55 | x |
| 2010-12-31 | NT$12.75 | NT$36.55 | x |
| 2011-12-31 | NT$12.73 | NT$36.55 | x |
| 2012-12-31 | NT$12.43 | NT$36.55 | x |
| 2013-12-31 | NT$16.67 | NT$36.55 | x |
| 2014-12-31 | NT$14.28 | NT$36.55 | x |
| 2015-12-31 | NT$19.75 | NT$36.55 | x |
| 2016-12-31 | NT$21.02 | NT$36.55 | x |
| 2017-12-31 | NT$21.17 | NT$36.55 | x |
| 2018-12-31 | NT$20.31 | NT$36.55 | x |
| 2019-12-31 | NT$21.79 | NT$36.55 | x |
| 2020-12-31 | NT$21.78 | NT$36.55 | x |
| 2021-12-31 | NT$22.13 | NT$36.55 | x |
| 2022-12-31 | NT$23.82 | NT$36.55 | x |
| 2023-12-31 | NT$23.50 | NT$36.55 | x |
| 2024-12-31 | NT$23.92 | NT$36.55 | x |
| 2025-12-31 | NT$24.64 | NT$36.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nang Kuang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.82%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.28%
- • Asset Turnover: 0.57x
- • Equity Multiplier: 1.54x
- Recent ROE (9.82%) is above the historical average (6.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 1.46% | 1.78% | 0.39x | 2.09x | NT$-69.67 Million |
| 2010 | -1.32% | -1.62% | 0.35x | 2.30x | NT$-90.92 Million |
| 2011 | 0.77% | 0.76% | 0.39x | 2.61x | NT$-74.07 Million |
| 2012 | 8.66% | 8.44% | 0.39x | 2.60x | NT$-12.43 Million |
| 2013 | -0.55% | -0.77% | 0.39x | 1.83x | NT$-150.38 Million |
| 2014 | 4.67% | 5.27% | 0.46x | 1.91x | NT$-76.86 Million |
| 2015 | 9.98% | 13.09% | 0.50x | 1.53x | NT$-444.80K |
| 2016 | 10.62% | 14.55% | 0.49x | 1.49x | NT$13.19 Million |
| 2017 | 8.67% | 12.36% | 0.45x | 1.56x | NT$-28.50 Million |
| 2018 | 4.93% | 6.58% | 0.51x | 1.47x | NT$-104.08 Million |
| 2019 | 9.94% | 12.34% | 0.54x | 1.50x | NT$-1.29 Million |
| 2020 | 8.32% | 10.45% | 0.54x | 1.48x | NT$-37.05 Million |
| 2021 | 8.75% | 11.02% | 0.52x | 1.53x | NT$-27.91 Million |
| 2022 | 14.60% | 18.14% | 0.54x | 1.49x | NT$110.90 Million |
| 2023 | 8.35% | 9.23% | 0.56x | 1.62x | NT$-39.30 Million |
| 2024 | 10.05% | 11.06% | 0.58x | 1.57x | NT$1.21 Million |
| 2025 | 9.82% | 11.28% | 0.57x | 1.54x | NT$-4.47 Million |
Industry Comparison
This section compares Nang Kuang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,752,688,333
- Average return on equity (ROE) among peers: 11.05%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nang Kuang Pharmaceutical Co Ltd (1752) | NT$2.49 Billion | 1.46% | 0.54x | $46.91 Million |
| St.Shine Optical Co Ltd (1565) | $5.39 Billion | 29.48% | 0.60x | $147.19 Million |
| Maxigen Biotech Inc (1783) | $1.14 Billion | 7.68% | 0.11x | $53.63 Million |
| SciVision Biotech Inc (1786) | $1.02 Billion | -2.16% | 0.07x | $107.95 Million |
| Bioteque (4107) | $1.88 Billion | 15.46% | 0.25x | $198.92 Million |
| Chi Sheng Chemical (4111) | $1.22 Billion | 12.60% | 0.47x | $41.85 Million |
| Sunder Biomedical Tech. Co., Ltd. (4115) | $790.45 Million | 1.68% | 0.80x | $2.11K |
| BenQ Medical Technology (4116) | $1.10 Billion | 2.62% | 0.78x | $25.45 Million |
| Pacific Hospital Supply Co Ltd (4126) | $2.26 Billion | 10.49% | 0.61x | $128.74 Million |
| Unicon Optical Co., Ltd. (4150) | $963.23 Million | 21.57% | 0.59x | $22.68 Million |